Canada's generic backlog tops 500 files with seven semaglutide submissions still waiting

Canada's Generic Pharmaceutical Association said more than 500 generic drug submissions are sitting at Health Canada, with over 100 formally classified as backlogged, and that seven generic semaglutide applications remain undecided ^[1]. At the time of this count, only two generic semaglutide injections had cleared review: one from Dr. Reddy's Laboratories and one from Apotex ^[1][2].

The backlog matters because Canada prices generics on a step-down schedule tied to how many competitors reach the market. Under the country's pan-Canadian pricing framework, a molecule's list price falls to 75% of the brand price once one generic launches, to 50% with two generics, and to 35% once three or more are selling ^[2]. Drug policy researcher Mina Tadrous of the University of Toronto told CBC News that pricing tiers work this way, and he estimated to The BMJ that once three generic semaglutide products are on shelves, out-of-pocket costs could land around $C100 a month ^[2]. With just two generics authorized and seven more still pending review, Canada has not yet hit that third-entrant threshold, so the deeper discount has not kicked in ^[1][2].

The generics only exist because of a paperwork gap. Novo Nordisk stopped paying a $C250 annual patent maintenance fee in Canada starting in 2018, and a separate regulatory exclusivity requirement expired on January 5, 2026; both had to lapse before competitors could file ^[2]. Tadrous said the non-payment may have been "a strategy on their part," noting it happened before semaglutide's full commercial boom ^[2]. Novo Nordisk has not explained the lapse publicly, telling The BMJ only that "all intellectual property decisions are carefully considered at the global level," and telling the BBC that the Canadian situation is "localized" and does not reflect the U.S. market, where exclusivity remains intact ^[2]. Patent expert Tahir Amin of the Initiative for Medicines, Access & Knowledge told the BBC the Canadian patent could have been extended to 2028 but was not renewed, saying "somebody dropped the ball" ^[2].

Dr. Reddy's generic became available in Canadian pharmacies on May 15, 2026 ^[2]. Apotex was authorized but had not announced a release date as of the same reporting ^[2]. Current pharmacy prices tracked by GLP1Prices.ca show brand-name Ozempic ranging from $86.40 to $663 CAD and Wegovy from $270 to $550 CAD, reflecting the wide variation across Canadian retailers before generic competition fully takes hold ^[2].

Why it matters for patients

This is a Canadian regulatory and pricing story, not a U.S. drug approval. Semaglutide's U.S. patents remain intact until 2032, and Novo Nordisk has told regulators the Canadian situation does not extend to the American market ^[2]. For U.S. patients, the relevance is comparative: Canada shows what happens to list prices once generic manufacturers can legally enter a GLP-1 market, something that is not yet possible for semaglutide in the United States. It also illustrates that generic entry does not immediately mean lower prices for everyone — Novo Nordisk has responded in Canada with brand-name discount cards and an advertising campaign encouraging patients to request brand Ozempic, and researchers expect the company to retain more market share than is typical after generic entry ^[2]. Novo Nordisk's own financial guidance reflects the pressure: the company forecast 2026 sales could fall 5% to 13%, and its share price dropped 17% the day that guidance was announced, with CEO Mike Doustdar calling 2026 "a year of unprecedented pricing pressure" ^[2].

What happens next

Health Canada has not given a timeline for clearing its backlog or deciding the seven pending semaglutide files ^[1]. Whether and when a third generic reaches the market — the threshold that triggers the deepest price cut under Canada's framework — depends on how quickly those reviews conclude ^[1][2].